Evidence map›Paper›PMID 37709746›Full record

ArticleNature communications2023

KMT2A associates with PHF5A-PHF14-HMG20A-RAI1 subcomplex in pancreatic cancer stem cells and epigenetically regulates their characteristics.

Mai Abdel Mouti, Siwei Deng, Martin Pook, Jessica Malzahn, Aniko Rendek, Stefania Militi, Reshma Nibhani, Zahir Soonawalla, Udo Oppermann, Chang-Il Hwang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Epigenetic regulation of cancer stemness.Signal transduction and targeted therapy · 2025
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Cancer Stem Cells from Definition to Detection and Targeted Drugs.International journal of molecular sciences · 2024
    Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Mai Abdel MoutiBotnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-3880-4541
Siwei DengBotnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-8155-5272
Martin PookBotnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Jessica MalzahnBotnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Aniko RendekDepartment of Histopathology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Stefania MilitiBotnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Reshma NibhaniBotnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-4344-2795
Zahir SoonawallaDepartment of Hepatobiliary and Pancreatic Surgery, Oxford University Hospitals NHS, Oxford, UK.
Udo OppermannBotnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Chang-Il HwangDepartment of Microbiology and Molecular Genetics, University of California Davis, Davis, USA.ORCID http://orcid.org/0000-0002-5710-7672
Siim PauklinBotnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK. siim.pauklin@ndorms.ox.ac.uk.ORCID http://orcid.org/0000-0001-8367-3670
Nuffield Orthopaedic Centre · GBOxford University Hospitals NHS Trust · GBUniversity of California, Davis · US

Funding

Engrailed-1 and Epigenetic Vulnerabilities in Metastatic Pancreatic CancerR37CA249007 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Chang-il Hwang · 2021 to 2026
$2.1M
Cancer Research UK 25064NCI NIH HHS R37 CA249007
6 · The paper itself

Abstract

Pancreatic cancer (PC), one of the most aggressive and life-threatening human malignancies, is known for its resistance to cytotoxic therapies. This is increasingly ascribed to the subpopulation of undifferentiated cells, known as pancreatic cancer stem cells (PCSCs), which display greater evolutionary fitness than other tumor cells to evade the cytotoxic effects of chemotherapy. PCSCs are crucial for tumor relapse as they possess 'stem cell-like' features that are characterized by self-renewal and differentiation. However, the molecular mechanisms that maintain the unique characteristics of PCSCs are poorly understood. Here, we identify the histone methyltransferase KMT2A as a physical binding partner of an RNA polymerase-associated PHF5A-PHF14-HMG20A-RAI1 protein subcomplex and an epigenetic regulator of PCSC properties and functions. Targeting the protein subcomplex in PCSCs with a KMT2A-WDR5 inhibitor attenuates their self-renewal capacity, cell viability, and in vivo tumorigenicity.

Indexed as

PancreasPancreatic NeoplasmsHigh Mobility Group ProteinsHistone MethyltransferasesHumansIntracellular Signaling Peptides and ProteinsNeoplastic Stem CellsResearch PersonnelRNA-Binding ProteinsTrans-ActivatorsHigh Mobility Group ProteinsHistone MethyltransferasesHMG20A protein, humanIntracellular Signaling Peptides and ProteinsPHF5A protein, humanRNA-Binding ProteinsTrans-ActivatorsWDR5 protein, human

Identifiers

PMID37709746
PMCPMC10502114
OpenAlexW4386741533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.